PRESENTER

DAY

TITLE

Agenda

June 24-27, 2026

Wednesday, June 24

TIME

6:00pm -7:30pm

TITLE

Faculty Dinner

Thursday, June 25 | Day 1 — Obesity

TIME

7:00am-8:00am

TITLE

 Breakfast & Registration

Session 1: Obesity

Moderators: Carel Le Roux and Ildiko Lingvay

TIME

8:00am-8:10am

TITLE

Opening Remarks of the SOLAR Conference 

PRESENTER

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc

TIME

8:10am-8:30am


TITLE

State of the Art Lecture: The Evolving Understanding of the Disease of Obesity that is Impacting Clinical Trials

PRESENTER

Carel Le Roux MD, PhD

Carel Le Roux MD, PhD

TIME

8:30am-8:45am

TITLE

Panel discussion

TIME

8:45am-9:05am


TITLE

What did we learn with the STEP and SELECT trials with Semaglutide that changed how we want to do clinical trials now?

PRESENTER

Dominica Rubino, MD

Dominica Rubino, MD

TIME

9:05am-9:20am

TITLE

Panel discussion

TIME

9:20am-9:40am

TITLE

What did we learn with the SURMOUNT trials with Tirzepatide that changed how we do clinical trials now?

PRESENTER

Layla AboShamat, MD

Layla AboShamat, MD

TIME

9:40am-9:55am

TITLE

Discussion

PRESENTER

Carel Le Roux, Dominica Rubino, Layla AboShamat, Ildiko Lingvay, Julia Dunn, Abd Tahrani

Carel Le Roux, Dominica Rubino, Layla AboShamat, Ildiko Lingvay, Julia Dunn, Abd Tahrani

TIME

9:55am-10:10am

TITLE

Break

TIME

10:10am-10:35am

TITLE

What did we learn with the new phase 2 and 3 trials with Multihormone Agonists that changed how we want to do clinical trials now?

PRESENTER

Ildiko Lingvay, MD

Ildiko Lingvay, MD

TIME

10:35am-11:00am


TITLE

Panel discussion

PRESENTER

Carel Le Roux, Dominica Rubino,  Ildiko Lingvay, Dimple Desai, Julia Dunn, Isabel Kloer, Abd Tahrani, Georgios Dimitriadis

Carel Le Roux, Dominica Rubino,  Ildiko Lingvay, Dimple Desai, Julia Dunn, Isabel Kloer, Abd Tahrani, Georgios Dimitriadis

TIME

11:00am-12:00pm

TITLE

Ipsen Pharmaceuticals Product Theater (Lunch) 

Session 2: Cholestatic Liver Disease / Genetic Liver Disease / and Hepatitis B

Moderators: Raj Vuppalanchi and Lily Dara 

TIME

12:00pm-12:20pm

TITLE

PBC Update: Current Status and Future Directions 

PRESENTER

Raj Vuppalanchi, MD

Raj Vuppalanchi, MD

TIME

12:20pm-12:40pm

TITLE

PSC/AIH/Other Autoimmune Liver Diseases: Novel Agents and Promising Trials

PRESENTER

Lily Dara 

Lily Dara 

TIME

12:40pm-1:00pm

TITLE

Genetic Liver Diseases 1: What's New in A1AT Deficiency, Wilson Disease, and Hemochromatosis

PRESENTER

Kris Kowdley, MD

Kris Kowdley, MD

TIME

1:00pm-1:20pm

TITLE

Genetic Liver Disease 2: Genetic Cholestasis from PFIC to Alagille Syndrome to BASD

PRESENTER

Wing-Kin Syn, MD

Wing-Kin Syn, MD

TIME

1:20pm-1:40pm

TITLE

Discussion and Q&A

PRESENTER

Panel: Raj Vuppalanchi, Lily Dara, Kris Kowdley

Panel: Raj Vuppalanchi, Lily Dara, Kris Kowdley

Moderators: Norah Terrault 

TIME

1:40pm-2:00pm

TITLE

Practice Guidelines and Trials Challenges for Chronic HBV and HDV: Are We Moving the Needle?

PRESENTER

Theo Heller

Theo Heller

TIME

2:00pm-2:20pm

TITLE

Update on Clinical Trials of Novel Agents Targeting Functional Cure for HBV

PRESENTER

Norah Terrault, MD

Norah Terrault, MD

TIME

2:20pm-2:40pm

TITLE

CHB Treatment and HCV Elimination in 2030: Can we Predict the Future?

PRESENTER

Elizabeth C. Verna, MD

Elizabeth C. Verna, MD

TIME

2:40pm-3:00pm

TITLE

Discussion and Q&A

PRESENTER

Panel: Norah Terrault

Panel: Norah Terrault

TIME

3:00pm-3:20pm

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

TIME

3:20pm -6:00pm

TITLE

Meetings, Poster Viewing, and Self-Directed Learning

TIME

6:00pm-7:00pm

TITLE

Reception

Friday, June 26  | Day 2 — MASH


TIME

8:30am - 9:15am

TITLE

Gilead Product Theater (Breakfast) 

Session 3: Clinical & Research Implications in MASH

Moderators: Naim Alkhouri 

TIME

9:15am-9:40am

TITLE

The Stephen Harrison State of Art Lecture: MASH in 2026

PRESENTER

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc

TIME

9:40am-10:00am

TITLE

Resmetirom and Semaglutide are now FDA Approved: What Should Clinicians Do Today?

PRESENTER

Naim Alkhouri, MD

Naim Alkhouri, MD

TIME

10:00am-10:20am

TITLE

Current Update on Phase 3 Trials

PRESENTER

Rohit Loomba, MD

Rohit Loomba, MD

TIME

10:20am-10:35am

TITLE

Break

TIME

10:35am-10:55am

TITLE

RNA Interference and Genetic Therapies

PRESENTER

Naga Chalasani, MD

Naga Chalasani, MD

TIME

10:55am-11:15am

TITLE

PROs in MASH Trials, Which One and How to Implement

PRESENTER

Zobair Younossi, MD

Zobair Younossi, MD

TIME

11:15am -11:35am

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

TIME

11:35am-12:30pm

TITLE

Q&A and Panel Discussion 

PRESENTER

Panel: Naim Alkhouri, Christophe Arbet-Engels, Becky Taub, Manu Chakravarthy, Rohit Loomba, Zobair Younossi, Mazen Noureddin & Meena Bansal

Panel: Naim Alkhouri, Christophe Arbet-Engels, Becky Taub, Manu Chakravarthy, Rohit Loomba, Zobair Younossi, Mazen Noureddin & Meena Bansal

TIME

12:30pm-1:30pm

TITLE

Madrigal Pharmaceuticals Product Theater (Lunch) 

Session 4: NITs and Trials Design

Moderators: Mazen Noureddin and 

TIME

1:30pm-1:50pm

TITLE

NITs: The Reasonably Likely to Predict Outcomes and the path to full Validation

PRESENTER

Jorn Schattenberg, MD

Jorn Schattenberg, MD

TIME

1:50pm-2:10pm

TITLE

Update on the Role of liver biopsy in MASH trials: When do I use it?

PRESENTER

Cynthia Behling, MD

Cynthia Behling, MD

TIME

2:10pm-2:30pm

TITLE

Designing Non-Cirrhotic MASH Trials without Liver Biopsy: Pros & Cons

PRESENTER

Maru Rinella, MD

Maru Rinella, MD

TIME

2:30pm-2:50pm

TITLE

Designing Cirrhosis Trials

PRESENTER

Arun Sanyal, MD

Arun Sanyal, MD

TIME

2:50pm-3:10pm

TITLE

Panel and Q&A

PRESENTER

Panel: Mazen Noureddin, Stuart Kendrick, Jorn Schattenberg, Cynthia Behling, Maru Rinella, Michael Charlton

Panel: Mazen Noureddin, Stuart Kendrick, Jorn Schattenberg, Cynthia Behling, Maru Rinella, Michael Charlton

TIME

3:10pm-3:30pm

TITLE

CDs Abstract of Choice – 2 Orals @10 mins

Saturday, June 27 | Day 3 — MASH, MetALD and ALD

TIME

7:00am-8:00am

TITLE

Breakfast & CME or Product Theater 

Session 5: Dual Perspectives: Sponsors & Site Exchange

Moderators:

TIME

8:00am-8:20am

TITLE

Overcoming MASH Trials Difficulties, Liver Biopsy, Biomarkers and Retention

PRESENTER

Rashmee Patil, MD

Rashmee Patil, MD

TIME

8:20am-8:40am

TITLE

Use of GLP-1 and their Effect in MASH Trials: How to control and mitigate during trials

PRESENTER

Meena Bansal, MD

Meena Bansal, MD

TIME

8:40am-9:00am

TITLE

What is a Stellar MASH Site: The Sponsor’s Wish List

PRESENTER

Michelle Long, MD

Michelle Long, MD

TIME

9:00am-9:20am

TITLE

Panel and Q&A

PRESENTER

Panel: Ramy Younes, Meena Bansal, Rashmee Patil, Michelle Long, Hank Mansbach, Jason Campagna

Panel: Ramy Younes, Meena Bansal, Rashmee Patil, Michelle Long, Hank Mansbach, Jason Campagna

TIME

9:20am-9:30am

TITLE

Break

Session 6: Shark Tank: Innovative Biotech’s meet KOLs and Big Pharma (MASH)

Sharks: Mazen Noureddin, Naim Alkhouri, Bill Sillbold, Stuart Kendrick 

TIME

9:30am-9:45am

TITLE

Company 1  (Kryia)

TIME

9:45am-9:55am

TITLE

Sharks

TIME

9:55am-10:10am

TITLE

Company 2 (HepaNova)

TIME

10:10am-10:20am

TITLE

Sharks

TIME

10:20am-10:35am

TITLE

Company 3 (Opko)

TIME

10:35am-10:45am

TITLE

Sharks

TIME

10:45am-11:15am

TITLE

Q&A

TIME

11:15am-12:15pm

TITLE

Boehringer Ingelheim Pharmaceuticals Product Theater (Lunch)

Session 7: The Future of MetALD and ALD

Moderators: Mazen Noureddin

TIME

12:15pm-12:35pm

TITLE

Current Update on Clinical Trials for MetALD and ALD

PRESENTER

Naim Alkhouri, MD

Naim Alkhouri, MD

TIME

12:35pm-12:55pm

TITLE

MetALD and ALD Phase 2 Trials Design

PRESENTER

Brian Lee, MD

Brian Lee, MD

TIME

12:55pm-1:15pm

TITLE

MetALD and ALD Phase 3 Trials Design

PRESENTER

Mazen Noureddin, MD

Mazen Noureddin, MD

TIME

1:15pm-1:30pm

TITLE

Q&A

Session 8: Dual Perspectives: Sponsors & Sites Exchange

Moderators: Gene Im & Belle Vivica Van Rosmalen

TIME

1:30pm-1:45pm

TITLE

How to Deal with Active Alcohol Intake during the trials

PRESENTER

Jessica Mellinger, MD 

Jessica Mellinger, MD 

TIME

1:45pm-2:00pm

TITLE

NIT in MetALD/ALD: The Reasonably Likely to Predict Outcomes

PRESENTER

Gene Im

Gene Im

TIME

2:00pm-2:20pm

TITLE

Sites Challenges in MetALD and ALD trials (Sites vs Sponsors Perspective (10 min each)

PRESENTER

Nikhil Vergis, MD (sponsor) & Manal Abdelmalek, MD (Site)

Nikhil Vergis, MD (sponsor) & Manal Abdelmalek, MD (Site)

TIME

2:20pm-2:40pm

TITLE

Panel and Q&A

PRESENTER

Panel: Ramy Younes, Nikhil Vergis, Manu Chakravarthy, Belle Vivica van Rosmalen, Maja Thiele

Panel: Ramy Younes, Nikhil Vergis, Manu Chakravarthy, Belle Vivica van Rosmalen, Maja Thiele

TIME

2:40pm – 2:50pm

TITLE

CDs Abstract of Choice – 1 Oral @10 mins

TIME

2:50pm-3:00pm

TITLE

Break

Session 9: Shark Tank: Innovative Biotechs meet KOLs and Big Pharma (ALD/MetALD)

Sharks: Jane Hsiao, Mazen Noureddin, Juan Pablo Arab, Nikhil Vergis and Brian Lee 

TIME

3:00pm-3:10pm

TITLE

Company 1 (Gyre)

TIME

3:10pm-3:20pm

TITLE

Sharks

TIME

3:20pm-3:40pm

TITLE

Company 2 (Altimmune)

TIME

3:40pm-3:50pm

TITLE

Sharks

TIME

4:00pm-4:15pm

TITLE

Closing Remarks

PRESENTER

Mazen Noureddin, MD & Naim Alkhouri, MD

Mazen Noureddin, MD & Naim Alkhouri, MD

Connecting liver, obesity, and metabolic science to improve patient care.

This conference looks at the bigger picture—how liver disease, obesity, and metabolic dysfunction intertwine. It creates a space where clinicians, researchers, and industry experts can break silos, share insights, and shape the future of care together. By weaving cutting-edge science with real-world clinical strategies, it challenges participants to rethink how breakthroughs move from the lab to the patient.